China approves Fosun Diagnostics’ COVID-19 antigen detection kit

Shanghai Fosun Pharmaceutical (Group) has announced that the novel coronavirus (2019nCoV) antigen detection kit (Colloidal Gold) developed by Fosun Diagnostics, a subsidiary company of Fosun Pharma has received approval from the China’s National Medical Products Administration (NMPA) for the commercial and clinical use of rapid antigen testing in COVID-19 screening. The kit has adopted the in- vitro qualitative detection method of Nucleocapsid antigen in nasopharyngeal swab samples from patients with respiratory and feverrelated symptoms within 7 days, quarantine observers, and other antigen detection needs. Fosun Diagnostics’ Novel Coronavirus Antigen Detection Kit is equipped with high sensitivity and specificity, strong anti-interference ability and no cross-reactivity among viruses and bacteria. The kit is easy to use and quick to operate and deliver results in 15 minutes. It has a variety of reagents to meet various testing needs at point of demand whenever required. Lately, the State Council of China under the Joint Prevention & Control for novel coronavirus pneumonia has decided to include antigen detection as a key supplement to nucleic acid detection under the “New Coronavirus Antigen Detection Application Plan (Pilot Trial)”.